Literature DB >> 8736616

The thrombocytopenic purpuras. Recognition and management.

S Gillis1.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP), are distinct entities. ITP is a relatively common autoimmune disorder typically manifesting with isolated thrombocytopenia. The acute form, more common in children, is a self-limiting, often post-viral disease. Therapy, if indicated, usually consists of a brief course of steroids or intravenous IgG. Chronic ITP, more common in adults, rarely remits spontaneously. Most patients respond initially to steroids, but generally the disease relapses when steroids are tapered. Splenectomy offers a 70% chance of cure. A variety of treatment options exist for patients not responding to splenectomy. The treating physician must choose the most effective and least toxic treatment for the individual patient. TTP is a rare, often life-threatening, multisystem disease of unknown aetiology. Its hallmark is widespread occlusion of the microcirculation by platelet aggregates. The clinical symptoms usually respond dramatically to plasma exchange therapy. Steroids, antiplatelet agents and vincristine may also be useful. Splenectomy should be considered in patients with multiple relapses. More specific therapy awaits a fuller understanding of the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8736616     DOI: 10.2165/00003495-199651060-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  102 in total

1.  Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion.

Authors:  M A Baumann; J E Menitove; R H Aster; T Anderson
Journal:  Ann Intern Med       Date:  1986-06       Impact factor: 25.391

2.  Ineffectiveness of high-dose intravenous gammaglobulin infusion in thrombotic thrombocytopenic purpura.

Authors:  J M Durand; P Lefevre; G Kaplanski; J Soubeyrand
Journal:  Am J Hematol       Date:  1993-02       Impact factor: 10.047

3.  Controversies in the management of acute idiopathic thrombocytopenic purpura: a survey of specialists.

Authors:  A S Dubansky; F A Oski
Journal:  Pediatrics       Date:  1986-01       Impact factor: 7.124

4.  Cyclosporin A therapy of immune-mediated thrombocytopenia in children.

Authors:  K R Schultz; C Strahlendorf; I Warrier; Y Ravindranath
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

5.  Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura.

Authors:  J F Patton; K R Manning; D Case; J Owen
Journal:  Am J Hematol       Date:  1994-10       Impact factor: 10.047

6.  Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis.

Authors:  J Pizzuto; R Ambriz
Journal:  Blood       Date:  1984-12       Impact factor: 22.113

7.  Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect.

Authors:  J B Bussel; J N Graziano; R P Kimberly; S Pahwa; L M Aledort
Journal:  Blood       Date:  1991-05-01       Impact factor: 22.113

8.  Treatment of chronic childhood immune thrombocytopenic purpura with intramuscular anti-D immunoglobulins.

Authors:  C Borgna-Pignatti; L Battisti; M Zecca; F Locatelli
Journal:  Br J Haematol       Date:  1994-11       Impact factor: 6.998

9.  Fetal platelet counts in thrombocytopenic pregnancy.

Authors:  C Kaplan; F Daffos; F Forestier; G Tertian; N Catherine; J C Pons; G Tchernia
Journal:  Lancet       Date:  1990-10-20       Impact factor: 79.321

10.  Chronic idiopathic thrombocytopenic purpura in the elderly.

Authors:  M Linares; A Cerveró; P Colomina; E Pastor; A López; A Pérez; M Perella; F Carbonell
Journal:  Acta Haematol       Date:  1995       Impact factor: 2.195

View more
  2 in total

Review 1.  Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS): the new thinking.

Authors:  J Liu; M Hutzler; C Li; L Pechet
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

2.  Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients.

Authors:  Mark Levandovsky; Danielle Harvey; Primo Lara; Ted Wun
Journal:  J Hematol Oncol       Date:  2008-12-01       Impact factor: 17.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.